XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $24.26 and traded as high as $27.86. XOMA Royalty shares last traded at $27.71, with a volume of 83,329 shares trading hands.
Analyst Ratings Changes
XOMA has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of XOMA Royalty from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. HC Wainwright reaffirmed a "buy" rating and set a $104.00 price objective on shares of XOMA Royalty in a research report on Wednesday, May 28th. Finally, Benchmark initiated coverage on shares of XOMA Royalty in a research report on Thursday, April 17th. They set a "buy" rating and a $35.00 price objective for the company.
Get Our Latest Stock Analysis on XOMA Royalty
XOMA Royalty Price Performance
The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 1.18. The stock has a market cap of $324.87 million, a price-to-earnings ratio of -23.60 and a beta of 0.93. The company's 50-day moving average is $25.57 and its 200-day moving average is $24.24.
XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.32. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. The firm had revenue of $15.91 million during the quarter, compared to analyst estimates of $6.75 million. Equities research analysts expect that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.
Insider Activity
In other XOMA Royalty news, CEO Owen Hughes sold 25,637 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total transaction of $650,667.06. Following the sale, the chief executive officer directly owned 62,701 shares of the company's stock, valued at approximately $1,591,351.38. This represents a 29.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the company's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the sale, the insider directly owned 1,267,545 shares in the company, valued at $34,350,469.50. This represents a 23.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.10% of the company's stock.
Institutional Trading of XOMA Royalty
Several large investors have recently added to or reduced their stakes in the company. Woodline Partners LP grew its stake in shares of XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company's stock valued at $3,359,000 after purchasing an additional 12,284 shares during the last quarter. Stonepine Capital Management LLC grew its stake in shares of XOMA Royalty by 3.3% during the first quarter. Stonepine Capital Management LLC now owns 129,813 shares of the biotechnology company's stock valued at $2,587,000 after purchasing an additional 4,113 shares during the last quarter. Eversept Partners LP grew its stake in shares of XOMA Royalty by 1.2% during the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock valued at $2,508,000 after purchasing an additional 1,128 shares during the last quarter. Northern Trust Corp grew its stake in shares of XOMA Royalty by 1.5% during the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock valued at $2,396,000 after purchasing an additional 1,340 shares during the last quarter. Finally, CM Management LLC grew its stake in shares of XOMA Royalty by 16.4% during the first quarter. CM Management LLC now owns 64,000 shares of the biotechnology company's stock valued at $1,276,000 after purchasing an additional 9,000 shares during the last quarter. 95.92% of the stock is owned by institutional investors.
About XOMA Royalty
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
See Also
Before you consider XOMA Royalty, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA Royalty wasn't on the list.
While XOMA Royalty currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
